Abstract

No reliable biomarkers exist to predict response to CDK4/6 inhibitors (CDK4/6i) in patients (pts) with metastatic breast cancer (MBC). FDG-PET scan, thanks to its sensitivity in detecting early metabolic changes in the tumour, could identify pts who will benefit from CDK4/6i.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract P4-01-09: Characterization of breast cancer brain metastases overall and progression-free survival and timing of cyclin-dependent kinase 4/6 inhibitor use: Retrospective single institution experience
Sonya Chew Minmin ...
American Journal of Cancer | VOL. 83
Sonya Chew Minmin, et. al.Sonya Chew Minmin ...
01 Mar 2023
Abstract P1-18-08: Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
Stephen Chia ... Christina Arce
American Journal of Cancer | VOL. 82
Stephen Chia, et. al.Stephen Chia ... Christina Arce
15 Feb 2022
Real-world analysis of disease progression after CDK 4/6 inhibitor (CDKi) therapy in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC).
Malinda West ... Zahi Ibrahim Mitri
Journal of Clinical Oncology | VOL. 39
Malinda West, et. al.Malinda West ... Zahi Ibrahim Mitri
20 May 2021
Abstract PD2-07: Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
Hope S Rugo ... Florence Lerebours
American Journal of Cancer | VOL. 81
Hope S Rugo, et. al.Hope S Rugo ... Florence Lerebours
15 Feb 2021
View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title
Journal
Date
Author
Neratinib and Ado-Trastuzumab-Emtansine for Pre-treated and Untreated HER2-positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022
R.A Freedman ... N.U Lin
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
R.A Freedman, et. al.R.A Freedman ... N.U Lin
06 Jul 2024
Primary tumor resection for asymptomatic colorectal cancer with unresectable metastasis: the end of the dilemma.
Sebastiano Biondo ... Esther Kreisler
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
Sebastiano Biondo, et. al.Sebastiano Biondo ... Esther Kreisler
03 Jul 2024
Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes
P Tarantino ... S M Tolaney
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
P Tarantino, et. al.P Tarantino ... S M Tolaney
01 Jul 2024
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia.
B Eichhorst ... C Buske
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
B Eichhorst, et. al.B Eichhorst ... C Buske
01 Jul 2024
View more papers